West Pharmaceutical reports Q4 EPS $1.83, consensus $1.78

Reports Q4 revenue $732M, consensus $739.47M. “We had strong 2023 base organic sales growth, excluding the headwinds from lower pandemic-related sales, led by high-value product (HVP) components and devices and contract manufacturing,” said Eric Green, president, CEO and chair of the board of directors. “Our continued investments in both HVP as well as contract manufacturing capacity to support customer demand will fuel our long-range financial construct of future organic sales growth and operating profit margin expansion.”